MedWatch

In spite of Covid-19 lock-downs and sent-home employees, GN have held on to R&D efforts

Even though the coronavirus pandemic led to employees being sent home and sales diving in 2020, hearing aid firm GN Hearing has steadfastly preserved its allocated resources for the development of new hearing aids, and now that a new product portfolio is on the market, CEO Gitte Aabo is confident 2021 will be a strong year.

GN Hearing CEO Gitte Aabo | Photo: GN Hearing / PR

Specialists such as engineers have defied the rampaging Covid-19 pandemic to work at full speed in the labs of Danish hearing aid firm GN Hearing, which did not allow the nightmarish year of 2020 to affect its innovative aspirations to deliver new and better products.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs